-
Amicus Therapeutics NASDAQ:FOLD Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
Location: 1 Cedarbrook Dr, New Jersey, 08512-3618, US | Website: www.amicusrx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.037B
Cash
249.8M
Avg Qtr Burn
-6.629M
Short % of Float
8.03%
Insider Ownership
0.76%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Galafold (migalastat) Details Fabry disease | Approved Quarterly sales | |
Approved Quarterly sales | ||
AT-GTX-501 Details Batten Disease | Failed Discontinued | |
AT-GTX-502 Details Batten Disease | Failed Discontinued |